93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy
暂无分享,去创建一个
M. Tsuboi | C. Swanton | M. Ahn | D. Harpole | J. Chaft | P. Dennis | F. Barlesi | C. Abbosh | D. Spigel | H. Mann | R. May | S. Peters